Media Kit

Short Bio (100 words)

Bari Gordon Vapnek, known as Brave Butterfly Bari, is a hypoparathyroidism advocate, columnist for Hypoparathyroidism News, and patient advocate. Diagnosed in 1998, Bari navigated a life-altering calcium crash in 2016 that transformed her into a passionate advocate. She was the first patient enrolled in the TransCon PTH clinical trial (Yorvipath), which received FDA approval in 2024. Through honest storytelling, speaking engagements, and community building, Bari empowers others living with hypoparathyroidism to embrace their journey with courage and hope.

Long Bio (250 words)

Bari Gordon Vapnek, known as Brave Butterfly Bari, is a nationally recognized hypoparathyroidism advocate, columnist, and patient advocate dedicated to transforming personal adversity into meaningful advocacy. Diagnosed with hypoparathyroidism in 1998, Bari's life changed dramatically in 2016 when she experienced a life-altering calcium crash that felt like a stroke. This pivotal moment ignited her commitment to advocacy and education.

Working with Dr. Mannstadt (2016-2019), Bari gained critical medical insights. In 2019, Dr. Karph's words—"There is hope, don't give up"—became a turning point. That same year, she met Dr. Rubin and became the first patient enrolled in the groundbreaking TransCon PTH clinical trial. Their partnership evolved into a powerful collaboration, hosting webinars and advancing patient education. The FDA approval of Yorvipath (Transcon PTH) in 2024 represents a historic breakthrough for millions living with hypoparathyroidism.

As a columnist for Hypoparathyroidism News, Bari shares her journey through powerful storytelling. She is a proud mother to Drew (26), a chiropractor at Lake Point Wellness, and Harrison (24), a sports director at KALB. Through writing, speaking, and community building, Bari empowers others to embrace their journey with courage, proving that our struggles can become our greatest strengths.